Retroperitoneal Sarkomlar ve Tedavi Yaklaşımı

Swallow CJ, Strauss DC, Bonvalot S, et al. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. Annals of Surgical Oncology. 2021;28(12):7873-7888. doi:10.1245/s10434-021-09654-z

Tseng WH, Martinez SR, Do L, Tamurian RM, Borys D, Canter RJ. Lack of Survival Benefit Following Adjuvant Radiation in Patients with Retroperitoneal Sarcoma: A SEER Analysis. Journal of Surgical Research. 2011;168(2):e173-e180. doi:10.1016/j.jss.2011.02.004

Morosi C, Stacchiotti S, Marchianò A, et al. Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: Analysis of 291 consecutive patients at a tertiary reference sarcoma center. European Journal of Surgical Oncology (EJSO). 2014;40(12):1662-1670. doi:10.1016/j.ejso.2014.10.005

Dominguez DA, Sampath S, Agulnik M, et al. Surgical Management of Retroperitoneal Sarcoma. Current Oncology. 2023;30(5):4618-4631. doi:10.3390/curroncol30050349

Munoz P, Bretcha-Boix P, Artigas V, Asencio JM. Surgical Principles of Primary Retroperitoneal Sarcoma in the Era of Personalized Treatment: A Review of the Frontline Extended Surgery. Cancers (Basel). 2022;14(17):4091. doi:10.3390/cancers14174091

Othman H, Shapiro J, Chung P, Gladdy RA. Progress in Retroperitoneal Sarcoma Management: Surgical and Radiotherapy Approaches. Seminars in Radiation Oncology. 2024;34(2):164-171. doi:10.1016/j.semradonc.2024.02.002

Nureta TH, Shale WT, Belete TD. Giant retroperitoneal well differentiated liposarcoma: A case report and literature review. International Journal of Surgery Case Reports. 2023;110:108679. doi:10.1016/j.ijscr.2023.108679

de Bree E, Michelakis D, Heretis I, et al. Retroperitoneal Soft Tissue Sarcoma: Emerging Therapeutic Strategies. Cancers (Basel). 2023;15(22):5469. doi:10.3390/cancers15225469

Gama JM, Almeida R, Oliveira RC, Casanova J. When Vessels and Sarcomas Combine: A Review of the Inferior Vena Cava Leiomyosarcoma. Journal of Vascular Diseases. 2024;3(1):34-48. doi:10.3390/jvd3010003

Yoshizawa K, Ohno Y, Kurata T, et al. Primary leiomyosarcoma of the inferior vena cava in a pediatric case: a case report and literature review. Surgical Case Reports. 2023;9(1):52. doi:10.1186/s40792-023-01630-x

Wang J, Grignol VP, Gronchi A, Luo CH, Pollock RE, Tseng WW. Surgical management of retroperitoneal sarcoma and opportunities for global collaboration. Chinese Clinical Oncology. 2018;7(4):39-39. doi:10.21037/cco.2018.07.05

Prendergast KM, Crago AM. Multi-Disciplinary Management of Retroperitoneal Sarcomas. Current Surgery Reports. 2024;12(11):417-424. doi:10.1007/s40137-024-00428-6

Garcia-Ortega DY. Comprehensive treatment strategy for improving surgical resection rate of retroperitoneal sarcomas: a histology-specific approach narrative review. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1432900

Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Annals of Oncology. 2021;32(11):1348-1365. doi:10.1016/j.annonc.2021.07.006

Schmitz E, Nessim C. Retroperitoneal Sarcoma Care in 2021. Cancers (Basel). 2022;14(5):1293. doi:10.3390/cancers14051293

Thway K, Wang J, Swansbury J, Min T, Fisher C. Fluorescence In Situ Hybridization for MDM2 Amplification as a Routine Ancillary Diagnostic Tool for Suspected Well-Differentiated and Dedifferentiated Liposarcomas: Experience at a Tertiary Center. Sarcoma. 2015;2015:1-10. doi:10.1155/2015/812089

Gambella A, Bertero L, Rondón-Lagos M, et al. FISH Diagnostic Assessment of MDM2 Amplification in Liposarcoma: Potential Pitfalls and Troubleshooting Recommendations. International Journal of Molecular Sciences. 2023;24(2):1342. doi:10.3390/ijms24021342

Miettinen M. Immunohistochemistry of soft tissue tumours – review with emphasis on 10 markers. Histopathology. 2014;64(1):101-118. doi:10.1111/his.12298

Demicco EG, Boland GM, Brewer Savannah KJ, et al. Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value. Histopathology. 2015;66(5):627-638. doi:10.1111/his.12466

Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Modern Pathology. 2014;27(3):390-395. doi:10.1038/modpathol.2013.164

Koelsche C, Schweizer L, Renner M, et al. Nuclear relocation of STAT 6 reliably predicts NAB2 – STAT6 fusion for the diagnosis of solitary fibrous tumour. Histopathology. 2014;65(5):613-622. doi:10.1111/his.12431

Cleven AHG, Sannaa GA Al, Briaire-de Bruijn I, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Modern Pathology. 2016;29(6):582-590. doi:10.1038/modpathol.2016.45

Pekmezci M, Cuevas-Ocampo AK, Perry A, Horvai AE. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Modern Pathology. 2017;30(12):1710-1719. doi:10.1038/modpathol.2017.97

Prieto-Granada CN, Wiesner T, Messina JL, Jungbluth AA, Chi P, Antonescu CR. Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST. American Journal of Surgical Pathology. 2016;40(4):479-489. doi:10.1097/PAS.0000000000000564

Bonvalot S, Raut CP, Pollock RE, et al. Technical Considerations in Surgery for Retroperitoneal Sarcomas: Position Paper from E-Surge, a Master Class in Sarcoma Surgery, and EORTC–STBSG. Annals of Surgical Oncology. 2012;19(9):2981-2991. doi:10.1245/s10434-012-2342-2

Weimann A, Braga M, Carli F, et al. ESPEN practical guideline: Clinical nutrition in surgery. Clinical Nutrition. 2021;40(7):4745-4761. doi:10.1016/j.clnu.2021.03.031

Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 2023;41(16):3063-3071. doi:10.1200/JCO.23.00294

Sotto KT, Burian BK, Brindle ME. Impact of the WHO Surgical Safety Checklist Relative to Its Design and Intended Use: A Systematic Review and Meta-Meta-Analysis. Journal of the American College of Surgeons. 2021;233(6):794-809e8. doi:10.1016/j.jamcollsurg.2021.08.692

Murphy MF, Harris A, Neuberger J. Consent for blood transfusion: summary of recommendations from the Advisory Committee for the Safety of Blood, Tissues and Organs (SaBTO). Clinical Medicine. 2021;21(3):201-203. doi:10.7861/clinmed.2020-1035

von Mehren M, Kane JM, Agulnik M, et al. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2022;20(7):815-833. doi:10.6004/jnccn.2022.0035

Erratum to: Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. Annals of Surgical Oncology. 2017;24(S3):688-689. doi:10.1245/s10434-017-5889-0

van Houdt WJ, Fiore M, Barretta F, et al. Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG. Cancer. 2020;126(22):4917-4925. doi:10.1002/cncr.33139

Raut CP, Callegaro D, Miceli R, et al. Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. Clinical Cancer Research. 2019;25(8):2664-2671. doi:10.1158/1078-0432.CCR-18-2700

Zerhouni S, Van Coevorden F, Swallow CJ. The role and outcomes of palliative surgery for retroperitoneal sarcoma. Journal of Surgical Oncology. 2018;117(1):105-110. doi:10.1002/jso.24934

Janes LA, Angeles C V. The Role of Surgery in Oligometastatic Retroperitoneal Sarcoma. Current Oncology. 2023;30(6):5240-5250. doi:10.3390/curroncol30060398

Thalji SZ, Tsai S, Gamblin TC, et al. Outcomes of palliative‐intent surgery in retroperitoneal sarcoma—Results from the US Sarcoma Collaborative. Journal of Surgical Oncology. 2020;121(7):1140-1147. doi:10.1002/jso.25890

Paul Olson TJ, Pinkerton C, Brasel KJ, Schwarze ML. Palliative Surgery for Malignant Bowel Obstruction From Carcinomatosis. JAMA Surgery. 2014;149(4):383. doi:10.1001/jamasurg.2013.4059

Walter M, Hansen E, Hamid S, et al. Palliative Management of Inoperable Malignant Bowel Obstruction: Prospective, Open Label, Phase 2 Study at an NCI Comprehensive Cancer Center. Journal of Pain and Symptom Management. 2024;67(1):20-26. doi:10.1016/j.jpainsymman.2023.09.014

Brindle M, Nelson G, Lobo DN, Ljungqvist O, Gustafsson UO. Recommendations from the ERAS® Society for standards for the development of enhanced recovery after surgery guidelines. British Journal of Surgery Open. 2020;4(1):157-163. doi:10.1002/bjs5.50238

Sauro KM, Smith C, Ibadin S, et al. Enhanced Recovery After Surgery Guidelines and Hospital Length of Stay, Readmission, Complications, and Mortality. JAMA Network Open. 2024;7(6):e2417310. doi:10.1001/jamanetworkopen.2024.17310

Gustafsson UO, Scott MJ, Hubner M, et al. Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS ® ) Society Recommendations: 2018. World Journal of Surgery. 2019;43(3):659-695. doi:10.1007/s00268-018-4844-y

Nessim C, Raut CP, Callegaro D, et al. Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). Annals of Surgical Oncology. 2021;28(5):2705-2714. doi:10.1245/s10434-020-09445-y

MacNeill AJ, Gronchi A, Miceli R, et al. Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma. Annals of Surgery. 2018;267(5):959-964. doi:10.1097/SLA.0000000000002250

Bagaria SP, Swallow C, Suraweera H, et al. Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. Annals of Surgical Oncology. 2021;28(11):6882-6889. doi:10.1245/s10434-021-09739-9

Rose KM, Huelster HL, Roberts EC, Manley BJ, Gilbert SM, Sexton WJ. Contemporary Management of Chylous Ascites after Retroperitoneal Surgery: Development of an Evidence-Based Treatment Algorithm. Journal of Urology. 2022;208(1):53-61. doi:10.1097/JU.0000000000002494

Lv S, Wang Q, Zhao W, et al. A review of the postoperative lymphatic leakage. Oncotarget. 2017;8(40):69062-69075. doi:10.18632/oncotarget.17297

Prowle JR, Forni LG, Bell M, et al. Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative. Nature Reviews Nephrology. 2021;17(9):605-618. doi:10.1038/s41581-021-00418-2

Kim WH, Shin KW, Ji SH, et al. Robust Association between Acute Kidney Injury after Radical Nephrectomy and Long-term Renal Function. Journal of Clinical Medicine. 2020;9(3):619. doi:10.3390/jcm9030619

Ghose J, Bhamre R, Mehta N, et al. Resection of the Inferior Vena Cava for Retroperitoneal Sarcoma: Six Cases and a Review of Literature. Indian Journal of Surgical Oncology. 2018;9(4):538-546. doi:10.1007/s13193-018-0796-9

De Crignis L, Guesnon M, Morin A, et al. Clinical outcomes after inferior vena cava resection for malignant disease. A single center experience of 51 vena cava resections. European Journal of Surgical Oncology. 2024;50(6):108253. doi:10.1016/j.ejso.2024.108253

Baia M, Ford SJ, Dumitra S, et al. Follow-up of patients with retroperitoneal sarcoma. European Journal of Surgical Oncology. 2023;49(6):1125-1132. doi:10.1016/j.ejso.2022.02.016

Noebauer-Huhmann IM, Vilanova JC, Papakonstantinou O, et al. Soft tissue tumor imaging in adults: European Society of Musculoskeletal Radiology–Guidelines 2024: imaging immediately after neoadjuvant therapy in soft tissue sarcoma, soft tissue tumor surveillance, and the role of interventional radiology. European Radiology. 2024;35(6):3324-3335. doi:10.1007/s00330-024-11242-0

Whitaker J, Nessim C, Almond M, Ford SJ. Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma. Current Oncology. 2023;30(3):2781-2791. doi:10.3390/curroncol30030211

Zaidi MY, Cardona K. Post-operative surveillance in soft tissue sarcoma: using tumor-specific recurrence patterns to direct approach. Chinese Clinical Oncology. 2018;7(4):45-45. doi:10.21037/cco.2018.08.03

Haas R, Stelmes J, Zaffaroni F, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092‐22092 STRASS trial. Cancer. 2022;128(14):2796-2805. doi:10.1002/cncr.34239

Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology. 2020;21(10):1366-1377. doi:10.1016/S1470-2045(20)30446-0

National Library of Medicine (NIH), ClinicalTrials.gov; Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (STRASS2) (24.08.2025 tarihinde https://clinicaltrials.gov/study/NCT04031677?term=STRASS-2&rank=1 adresinden ulaşılmıştır.)

Rain Oncology Inc., Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma (24.08.2025 tarihinde https://www.rainoncology.com/news-press-releases/rain-oncology-announces-topline-results-from-phase-3-mantra-trial-of-milademetan-for-the-treatment-of-dedifferentiated-liposarcoma adresinden ulaşılmıştır.)

Dickson MA, Schwartz GK, Keohan ML, et al. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib. JAMA Oncology. 2016;2(7):937. doi:10.1001/jamaoncol.2016.0264

Pautier P, Italiano A, Piperno-Neumann S, et al. Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. New England Journal of Medicine. 2024;391(9):789-799. doi:10.1056/NEJMoa2403394

Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of Clinical Oncology. 2016;34(8):786-793. doi:10.1200/JCO.2015.62.4734

Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2016;387(10028):1629-1637. doi:10.1016/S0140-6736(15)01283-0

Lawless A, Zhou DDX, McDonough J, et al. The role of radiation therapy in the management of primary retroperitoneal sarcoma: A systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma Association. Cancer Treatment Reviews. 2023;120:102620. doi:10.1016/j.ctrv.2023.102620